Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Global CardiologyOpen Access

Lipoprotein a: what clinicians need to know

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLaibah Arshad KhanMHMuhammad Farhan HanifARAhmed Mustafa Rashid

Discussion

Loading...

Member takes

Overview

Lipoprotein(a) levels significantly impact cardiovascular disease risk, highlighting the need for screening and treatment options.

Key Points

  • Elevated Lp(a) levels are found in about 20% of the global population, indicating a widespread health concern.
  • Genetic factors predominantly influence Lp(a) levels, which are highest in Black individuals and lower in East Asians.
  • Recent interventions like PCSK9 inhibitors and novel RNA-based therapies can significantly reduce elevated Lp(a) levels.
  • Despite recommendations for screening, Lp(a) testing is underutilized, with only 0.3% of patients being tested in the US.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/68c239e5b210217d6477e591https://doi.org/10.4081/cardio.2025.80
View Full Paper
Ask AI
Bookmark
Share